Nephrology Topic

Hyponatremia.

The full stepwise approach: confirm true hypotonicity (and the acute vs chronic distinction), read urine osmolality (ADH on/off) then urine sodium (avid <20 vs wasting >40), separate SIAD from its mimics with the FE indices, and correct safely — goals vs limits, ODS risk, the DDAVP brake, and the desalination and potassium-repletion traps.

Reviewed June 2026 · verify against current guidelines

Diagnosis & Workup

Step 1: Confirm tonicity and timing.

Is it truly hypotonic?

Acute or chronic sets the danger

Ask two things first: is it truly hypotonic, and how long has it been? Duration decides how fast you may go.
Diagnosis & Workup

Step 2: Urine osmolality.

Is ADH on or off?

Watch the ADH-off group

A maximally dilute urine (under 100) means the kidney is doing its job; the problem is water intake or low solute.
ADH antidiuretic hormone
Diagnosis & Workup

Step 3: Urine sodium.

Urine Na splits the cause (when ADH is on)

Na avid (UNa <20)Low effective arterial volume. Then look: dry = true hypovolemia (GI or skin loss); edematous = heart failure, cirrhosis, nephrotic.
Na wasting (UNa >40)Euvolemic SIAD; also diuretics, salt wasting, adrenal insufficiency, advanced kidney disease.

Read it with the volume exam

Sodium avid (urine Na under 20) is the low-volume signature; sodium wasting (over 40) points to SIAD or a renal cause.
UNa urine sodiumSIAD syndrome of inappropriate antidiuresisFE fractional excretionGI gastrointestinal
Diagnosis & Workup

SIAD and its mimics.

SIAD is a diagnosis of exclusion

SIAD vs low effective volume

FE urea<35% favors low volume; >55% favors SIAD. Use when FENa is unreliable on diuretics.
FE uric acid≥12% supports SIAD; <8% favors low effective volume.

Do not confuse these

FE indices help on diuretics, but they cannot separate SIAD from cerebral salt wasting; only volume status does.
SIAD syndrome of inappropriate antidiuresisFE fractional excretionFENa fractional excretion of sodiumBUN blood urea nitrogenTSH thyroid-stimulating hormone
Acute Management

Severe symptoms and safe correction.

When to reach for 3% saline

Goals and limits

Goal (symptomatic)Raise 4 to 6 mEq, then hold.
Limit per 24 h≤8 mEq/L; ≤6 if high ODS risk.
Limit per 48 h≤18 mEq/L.
High ODS riskAlcohol, malnutrition, low K, liver disease, Na <105. ODS is unlikely if starting Na is over 120.

Brakes on correction

Overcorrecting chronic hyponatremia causes osmotic demyelination, often irreversible. Guideline limits stay the safe default, though faster correction is under active reappraisal.
ODS osmotic demyelination syndromeDDAVP desmopressin
Pitfalls & Disposition

Treatment by type. What gets missed.

Treatment by volume

HypovolemicIsotonic 0.9% saline; treat the loss. Na often autocorrects, so anticipate overcorrection.
Euvolemic / SIADFluid restrict; salt tabs, urea, an SGLT2 inhibitor, or a vaptan. Treat the cause.
HypervolemicFluid restrict and diurese; treat the heart, liver, or kidney.

Pitfalls

In SIAD, isotonic saline can paradoxically lower the sodium. Restrict water and treat the trigger.
SIAD syndrome of inappropriate antidiuresisSGLT2 sodium-glucose cotransporter-2 inhibitorSSRIs selective serotonin reuptake inhibitorsNSAIDs nonsteroidal anti-inflammatory drugs

Sources

Verify against current guidelines and local protocol before acting.

  1. Verbalis JG et al. Diagnosis, evaluation &amp; treatment of hyponatremia: expert panel recommendations. Am J Med 2013;126(10 Suppl 1):S1-42.
  2. Spasovski G et al. Clinical practice guideline on diagnosis and treatment of hyponatraemia. Eur J Endocrinol 2014;170:G1-47.
  3. Spasovski G. Hyponatraemia: treatment standard 2024. Nephrol Dial Transplant 2024;39(10):1583-92.
  4. Katz MA. Hyperglycemia-induced hyponatremia: expected serum sodium depression (the 1.6 mEq/L factor). N Engl J Med 1973;289(16):843-4.
  5. Hillier TA, Abbott RD, Barrett EJ. Evaluating the correction factor for hyperglycemia (the 2.4 mEq/L factor). Am J Med 1999;106(4):399-403.
  6. Fenske W et al. Value of fractional uric acid excretion in hyponatremic patients on diuretics. JCEM 2008;93(8):2991-7.
  7. Refardt J et al. Empagliflozin (SGLT2 inhibitor) in chronic SIAD: randomized crossover trial. J Am Soc Nephrol 2023;34(2):322-32.
  8. Mark DG et al. Sodium correction rates &amp; outcomes in severe hyponatremia: retrospective cohort. Ann Intern Med 2026;179(3):330-9.

Downloads

Every card for this topic — carousels and tables, print-ready for the wards or for sharing.

Hyponatremia.
Carousel8 slides